Bristol Myers Shares Phase 3 Results for Cobenfy in Schizophrenia Treatment Bristol Myers Squibb (NYSE: BMY) has announced the topline results from the Phase 3 ARISE trial, assessing the efficacy and safety of Cobenfy™ (xanomeline and trospium chloride) as an…
Metro Biotech Begins Phase 1a Trial Dosing for NAD Booster MIB-725 Metro International Biotech, LLC (MetroBiotech), a member of the EdenRoc Sciences family focused on developing advanced therapies for age-related diseases, has announced that the first patients in Cohort 1…
Validic, Tenovi Partner to Expand Remote Patient Monitoring Access Validic, a prominent digital health solutions provider, has announced a new integration with Tenovi, a top cellular-connected platform specializing in automated data capture from medical devices. This partnership aims to broaden…
Surmodics Publishes TRANSCEND Trial Results Showcasing SurVeil™ DCB Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, has announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating that the SurVeil™…
Vizgen Unveils MERFISH 2.0 and Enhanced OmniVUE Panels with ADC Biomarkers Vizgen, Inc., a pioneer in spatial genomics and proteomics, has announced the global commercial launch of MERFISH 2.0™, a next-generation spatial transcriptomics chemistry set to redefine the boundaries of…
Paubox: 95% of Healthcare Phishing Attacks Go Unreported Your health data may be more vulnerable than you think—and your healthcare provider might not even know it. A newly released report from Paubox reveals a troubling reality: 95% of phishing attacks…
Exact Sciences Launches Oncodetect™ MRD Test Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics and screening, has officially launched Oncodetect™, a next-generation test designed to detect molecular residual disease (MRD) in patients with solid tumors. The new test…
Perfuze Completes U.S. Trial Enrollment, Appoints Joe Rotger as EVP of Sales Perfuze, a leading innovator in next-generation catheter-based stroke treatment technologies, has announced two major developments in its mission to improve outcomes for patients with acute ischemic stroke. The…
Geron Announces New Hire Equity Grants Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company focused on transforming the treatment of hematologic malignancies, today announced the grant of inducement equity awards to 12 newly hired employees. These awards, approved under Nasdaq…
Scholar Rock Announces New Employee Equity Grants Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing innovative treatments for serious diseases, announced the issuance of inducement equity awards to 19 newly hired employees. These awards were granted in…